Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 81 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Patch Cap Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evoked Responses as Pharmacodynamic Biomarkers in Healthy and Schizophrenic Participants (MK-4334-007)

NCT05136690
View directory record Official record
Conditions
Cognitive Impairment Associated With Schizophrenia
Interventions
Nicotine patch, MK-4334, Placebo patch, Placebo capsule
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Long Beach, California • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced Sep 7, 2026, 10:22 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Kronos Early Estrogen Prevention Study (KEEPS)

NCT00154180
View directory record Official record
Conditions
Menopause, Arteriosclerosis
Interventions
Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo
Drug
Lead sponsor
Kronos Longevity Research Institute
Other
Eligibility
42 Years to 58 Years · Female only
Enrollment
728 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2009 · Synced Sep 7, 2026, 10:22 AM EDT
Not listed Phase 4 Interventional

Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy

NCT02800655
View directory record Official record
Conditions
HIV
Interventions
Digital Health Feedback System
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Sep 7, 2026, 10:22 AM EDT
Not listed Not applicable Interventional

Digital Health Feedback System (DHFS) for Longitudinal Monitoring of ARVs Used in HIV Pre-exposure Prophylaxis (PrEP)

NCT03693040
View directory record Official record
Conditions
HIV Prevention
Interventions
Digital Health Feedback System
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Sep 7, 2026, 10:22 AM EDT
Terminated Phase 4 Interventional

Lidocaine Patch Versus Celecoxib in Pain From Osteoarthritis of the Knee

NCT00904605
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Lidoderm, Celecoxib
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
20
States / cities
Hueytown, Alabama • Mesa, Arizona • Oro Valley, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 7, 2026, 10:22 AM EDT
Recruiting Phase 4 Interventional

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

NCT06610305
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 7, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

Cold Atmospheric Plasma Device for Pediatric Molluscum and Verruca

NCT05070754
View directory record Official record
Conditions
Verruca Vulgaris, Molluscum Contagiosum Skin Infection
Interventions
Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP), Cryotherapy, Canthardin Collodion
Device · Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
4 Years to 21 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Sep 7, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements

NCT01272830
View directory record Official record
Conditions
Edematous, Synovitis, Foreign Body Reaction, Osteolysis
Interventions
Placebo, Apatone®B
Drug
Lead sponsor
IC-MedTech Corporation
Industry
Eligibility
50 Years to 85 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 7, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)

NCT05343455
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
DFD-29, Doxycycline, Placebo
Drug
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
15
States / cities
Santa Monica, California • Doral, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 7, 2026, 10:22 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood

NCT03003949
View directory record Official record
Conditions
Perimenopausal Disorder, Stress, Emotional
Interventions
Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo Patch, Progesterone Capsule, Placebo Oral Capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 7, 2026, 10:22 AM EDT
Completed No phase listed Observational Results available

SCP Hip Outcomes Study

NCT03494660
View directory record Official record
Conditions
Subchondral Cysts, Subchondral Bone Edema, Bone Marrow Edema, Insufficiency Fractures, Avascular Necrosis of Hip, Femoroacetabular Impingement, Dysplasia; Hip
Interventions
Subchondroplasty Procedure with AccuFill
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
6
States / cities
Rancho Mirage, California • Gulf Breeze, Florida • Rockford, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 7, 2026, 10:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Estrogen and Serotonin on Changing Brain Chemistry

NCT01208324
View directory record Official record
Conditions
Menopause
Interventions
estrogen patch, Amino acids, Placebo Patch, Placebo pills
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
48 Years to 60 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Sep 7, 2026, 10:22 AM EDT
Completed Phase 1 Interventional Results available

Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

NCT02516813
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
M3814 100 mg, M3814 200 mg, M3814 300 mg, M3814 400 mg, M3814 50 mg, Fractionated RT, Cisplatin
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
9
States / cities
Fresno, California • Fort Lauderdale, Florida • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 7, 2026, 10:22 AM EDT
Withdrawn Not applicable Interventional

CONVERGE CAP Study-For The Treatment Of Symptomatic Persistent or Long-standing Persistent AF

NCT04239534
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Convergence Of Epicardial And Endocardial RF Ablation
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
8
States / cities
Birmingham, Alabama • Huntsville, Alabama • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 7, 2026, 10:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety,Usability and Compliance of Using C-Scan System for Providing Information on Colonic Polypoid Lesions and Masses

NCT03735407
View directory record Official record
Conditions
Colo-rectal Cancer
Interventions
C-Scan procedure
Device
Lead sponsor
Check-Cap Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 7, 2026, 10:22 AM EDT
Active, not recruiting Not applicable Interventional

CREST: Capsular Repair During Hip Arthroscopy

NCT03372564
View directory record Official record
Conditions
Hip Arthroscopy
Interventions
Hip Capsule Repair
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2040
U.S. locations
3
States / cities
Scottsdale, Arizona • Westmont, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Sep 7, 2026, 10:22 AM EDT
Active, not recruiting Phase 3 Interventional

Estrogen Administration for the Treatment of NASH in Postmenopausal Women

NCT04833140
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Estradiol patch, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 7, 2026, 10:22 AM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity

NCT06299891
View directory record Official record
Conditions
Hypothalamic Obesity, Hypothalamic Tumor, Craniopharyngioma
Interventions
Phentermine / Topiramate Extended Release Oral Capsule [Qsymia], Placebo
Drug · Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
6 Years to 28 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Sep 7, 2026, 10:22 AM EDT
Terminated No phase listed Observational Results available

SCP® Observational Study of the Knee

NCT03110224
View directory record Official record
Conditions
Bone Marrow Edema
Interventions
Subchondroplasty Procedure with AccuFill
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
14
States / cities
Parker, Colorado • Palm Beach Gardens, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Sep 7, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

NCT00852540
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retpamulin Ointment, 1%, Linezolid
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
2 Months and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
53
States / cities
Anniston, Alabama • Birmingham, Alabama • Bentonville, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 7, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Palm Tocotrienols in Chronic Hemodialysis (USA)

NCT02358967
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease
Interventions
TRF (Tocotrienol-rich-fraction), Placebo
Dietary Supplement
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Sep 7, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

NCT02792231
View directory record Official record
Conditions
Relapsing Multiple Scelrosis
Interventions
Ofatumumab subcutaneous injection, Teriflunomide-matching placebo capsules, Teriflunomide capsule, Matching placebo of ofatumumab subcutaneous injections
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
955 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
59
States / cities
Birmingham, Alabama • Cullman, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 7, 2026, 10:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine

NCT02420327
View directory record Official record
Conditions
Basic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic Receptor
Interventions
Placebo patch & placebo capsule, Placebo patch & galantamine capsule, Nicotine patch & placebo capsule, Nicotine patch and galantamine capsule
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Sep 7, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.

NCT05296629
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
DFD-29, Doxycycline, Placebo
Drug
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
27
States / cities
Rogers, Arkansas • Cerritos, California • Fremont, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 7, 2026, 10:22 AM EDT